Caribou Biosciences doses first patient in Phase 1 trial of CB-011 for multiple myeloma

Caribou Biosciences, Inc.

First patient dosed with CB-011 at dose level 1 (50x10^6 CAR-T cells) in CaMMouflage Phase 1 trial for relapsed/refractory multiple myeloma.
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking via B2M removal and B2M-HLA-E transgene insertion.
Trial is open-label, 3+3 dose escalation (Part A) followed by dose expansion (Part B); excludes prior CAR-T or BCMA therapy within 3 months.
CB-011 is Caribou's second allogeneic CAR-T program to enter the clinic.
Company plans to continue enrollment at dose level 1 and provide dose clearance updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.